Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T Lymphocytes

Journal of Virology

Volumn 88, Issue 18, 2014, Pages 10975-10981

  Su, Bin ^a   Laumond, Alexandre Lederle ^a,b   Ducloy, Camille ^a   Schmidt, Sylvie ^a   Decoville, Thomas ^a   Moog, Christiane ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL PROTEIN; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY VRC01; SAMHD1 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPX PROTEIN; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VRC01 MONOCLONAL ANTIBODY;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL MATURATION; COCULTURE; CROSS REACTION; CYTOKINE RELEASE; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREGULATION; INFECTION PREVENTION; LYMPHOCYTE ACTIVATION; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSMISSION; CELL CULTURE; DENDRITIC CELL; DRUG EFFECTS; HIV INFECTIONS; PHYSIOLOGY; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84906350508     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01748-14     Document Type: Article

References (65)

1. Mascola JR, Haynes BF. 2013. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254:225-244. http://dx.doi.org/10.1111/imr.12075.
2. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. 2013. Antibodies in HIV-1 vaccine development and therapy. Science 341:1199-1204. http://dx.doi.org/10.1126/science.1241144.
3. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13:693-701. http://dx.doi.org/10.1038/nri3516.
4. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
5. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P, Protocol G Principal Investigators. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
6. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817. http://dx.doi.org/10.1126/science.1192819.
7. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
8. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Jr., Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-280. http://dx.doi.org/10.1038/nature12746.
9. McCoy LE, Weiss RA. 2013. Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210:209-223. http://dx.doi.org/10.1084/jem.20121827.
10. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224-228.
11. Veselinovic M, Neff CP, Mulder LR, Akkina R. 2012. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432:505-510. http://dx.doi.org/10.1016/j.virol.2012.06.025.
12. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118-122. http://dx.doi.org/10.1038/nature11604.
13. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fatkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209:1469-1479. http://dx.doi.org/10.1084 /jem.20120423.
14. Fitzgerald-Bocarsly P, Jacobs ES. 2010. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J. Leukoc. Biol. 87:609-620. http://dx.doi.org/10.1189/jlb.0909635.
15. Liu YJ. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115633.
16. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835-1837. http://dx.doi.org/10.1126/science.284.5421.1835.
17. Sandgren KJ, Smed-Sorensen A, Forsell MN, Soldemo M, Adams WC, Liang F, Perbeck L, Koup RA, Wyatt RT, Karlsson Hedestam GB, Lore K. 2013. Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation. J. Immunol. 191:60-69. http://dx.doi.org/10.4049/jimmunol.1202489.
18. O'Brien M, Manches O, Bhardwaj N. 2013. Plasmacytoid dendritic cells in HIV infection. Adv. Exp. Med. Biol. 762:71-107. http://dx.doi.org/10.1189/jlb.0909635.
19. Miller E, Bhardwaj N. 2013. Dendritic cell dysregulation during HIV-1 infection. Immunol. Rev. 254:170-189. http://dx.doi.org/10.1111/imr.12082.
20. Smed-Sorensen A, Lore K, Vasudevan J, Louder MK, Andersson J, Mascola JR, Spetz AL, Koup RA. 2005. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J. Virol. 79:8861-8869. http://dx.doi.org/10.1128 /JVI.79.14.8861-8869.2005.
21. Patterson S, Rae A, Hockey N, Gilmour J, Gotch F. 2001. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J. Virol. 75:6710-6713. http: //dx.doi.org/10.1128/JVI.75.14.6710-6713.2001.
22. Bloch N, O'Brien M, Norton TD, Polsky SB, Bhardwaj N, Landau NR. 2014. HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. AIDS Res. Hum. Retroviruses 30:195-203. http://dx.doi.org/10.1089/aid.2013.0119.
23. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657. http://dx.doi.org/10.1038/nature10117.
24. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661. http://dx.doi.org/10.1038/nature10195.
25. Tristem M, Marshall C, Karpas A, Hill F. 1992. Evolution of the primate lentiviruses: evidence from Vpx and Vpr. EMBO J. 11:3405-3412.
26. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669. http://dx.doi.org/10.1038 /326662a0.
27. Evans VA, Lal L, Akkina R, Solomon A, Wright E, Lewin SR, Cameron PU. 2011. Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro. Retrovirology 8:43. http://dx.doi.org/10.1186/1742-4690-8-43.
28. Lore K, Smed-Sorensen A, Vasudevan J, Mascola JR, Koup RA. 2005. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4_ T cells. J. Exp. Med. 201:2023-2033. http://dx.doi.org/10.1084/jem.20042413.
29. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. 2002. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J. Virol. 76:11033- 11041. http://dx.doi.org/10.1128/JVI.76.21.11033-11041.2002.
30. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M, Jr., Lifson JD, Pope M, Cunningham AL. 2004. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103:2170-2179. http://dx.doi.org/10.1182/blood-2003-09-3129.
31. Su B, Xu K, Lederle A, Peressin M, Biedma ME, Laumond G, Schmidt S, Decoville T, Proust A, Lambotin M, Holl V, Moog C. 2012. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood 120:3708-3717. http://dx.doi.org /10.1182/blood-2012-03-418913.
32. Coleman CM, Gelais CS, Wu L. 2013. Cellular and viral mechanisms of HIV-1 transmission mediated by dendritic cells. Adv. Exp. Med. Biol. 762:109-130. http://dx.doi.org/10.1007/978-1-4614-4433-6_4.
33. McDonald D. 2010. Dendritic cells and HIV-1 trans-infection. Viruses 2:1704-1717. http://dx.doi.org/10.3390/v2081704.
34. Wu L, KewalRamani VN. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6:859-868. http: //dx.doi.org/10.1038/nri1960.
35. Su B, Biedma ME, Lederle A, Peressin M, Lambotin M, Proust A, Decoville T, Schmidt S, Laumond G, Moog C. 2014. Dendritic celllymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV-1 replication in dendritic cells. J. Virol. 88:5109-5121. http://dx.doi.org/10.1128/JVI.03057-13.
36. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
37. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr., Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110:6626-6633. http://dx.doi.org/10.1073/pnas.1304288110.
38. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. 2013. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 87:2401-2411. http://dx.doi.org/10.1128/JVI.02964-12.
39. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. 2012. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 86:2715- 2728. http://dx.doi.org/10.1128/JVI.06157-11.
40. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW. 2011. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 85:8514-8527. http://dx.doi.org /10.1128/JVI.00736-11.
41. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557. http://dx.doi.org/10.1073/pnas.0802203105.
42. Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, Hill BJ, Gabuzda D, Roederer M. 2002. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76:4810-4821. http://dx.doi.org/10.1128/JVI.76.10.4810-4821.2002.
43. Duncan CJ, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ. 2014. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J. Virol. 88:2025-2034. http://dx.doi.org/10.1128/JVI.03245-13.
44. Sagar M, Akiyama H, Etemad B, Ramirez N, Freitas I, Gummuluru S. 2012. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J. Infect. Dis. 205: 1248-1257. http://dx.doi.org/10.1093/infdis/jis183.
45. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A. 2012. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8:e1002634. http://dx.doi.org/10.1371/journal.ppat.1002634.
46. Rodriguez-Plata MT, Puigdomenech I, Izquierdo-Useros N, Puertas MC, Carrillo J, Erkizia I, Clotet B, Blanco J, Martinez-Picado J. 2013. The infectious synapse formed between mature dendritic cells and CD4(_) T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology 10:42. http://dx.doi.org/10.1186/1742-4690 -10-42.
47. Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JH, Kapsenberg ML, Berkhout B. 2002. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J. Virol. 76:7812-7821. http://dx.doi.org/10.1128/JVI.76.15.7812-7821.2002.
48. Kondo N, Melikyan GB. 2012. Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. PLoS One 7:e44827. http://dx.doi.org/10.1371/journal.pone.0044827.
49. Tardif MR, Gilbert C, Thibault S, Fortin JF, Tremblay MJ. 2009. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob. Agents Chemother. 53:4656-4666. http://dx.doi.org /10.1128/AAC.00117-09.
50. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker G, Mothes W. 2013. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One 8:e53138. http://dx.doi.org/10.1371/journal.pone.0053138.
51. Kulpa DA, Brehm JH, Fromentin R, Cooper A, Cooper C, Ahlers J, Chomont N, Sekaly RP. 2013. The immunological synapse: the gateway to the HIV reservoir. Immunol. Rev. 254:305-325. http://dx.doi.org/10.1111/imr.12080.
52. Hivroz C, Chemin K, Tourret M, Bohineust A. 2012. Crosstalk between T lymphocytes and dendritic cells. Crit. Rev. Immunol. 32:139-155. http: //dx.doi.org/10.1615/CritRevImmunol.v32.i2.30.
53. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristan C, Victora GD, Zanin-Zhorov A, Dustin ML. 2010. Functional anatomy of T cell activation and synapse formation. Annu. Rev. Immunol. 28:79-105. http://dx.doi.org/10.1146/annurev-immunol -030409-101308.
54. Dustin ML, Tseng SY, Varma R, Campi G. 2006. T cell-dendritic cell immunological synapses. Curr. Opin. Immunol. 18:512-516. http://dx.doi.org/10.1016/j.coi.2006.05.017.
55. Su B, Moog C. 2014. Which antibody functions are important for an HIV vaccine? Front. Immunol. 5:289. http://dx.doi.org/10.3389/fimmu.2014.00289.
56. Schiffner T, Sattentau QJ, Duncan CJ. 2013. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 31:5789-5797. http://dx.doi.org/10.1016/j.vaccine.2013.10.020.
57. Moris A. 2013. Antiviral treatments over cell-to-cell infection: is it just a matter of dose? AIDS 27:2481-2483. http://dx.doi.org/10.1097/01.aids.0000432447.45486.03.
58. Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid JF, Eden C, Mouquet H, Nussenzweig MC, Schwartz O. 2013. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J. Exp. Med. 210:2813-2821. http://dx.doi.org/10.1084/jem.20131244.
59. Wieland SF, Takahashi K, Boyd B, Whitten-Bauer C, Ngo N, de la Torre JC, Chisari FV. 2014. Human plasmacytoid dendritic cells sense lymphocytic choriomeningitis virus-infected cells in vitro. J. Virol. 88: 752-757. http://dx.doi.org/10.1128/JVI.01714-13.
60. Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, Chisari FV. 2010. Plasmacytoid dendritic cells sense hepatitis C virusinfected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. U. S. A. 107:7431-7436. http://dx.doi.org/10.1073/pnas.1002301107.
61. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, Chaperot L, Plumas J, Randall RE, Si-Tahar M, Mammano F, Albert ML, Schwartz O. 2011. Innate sensing of HIV-infected cells. PLoS Pathog. 7:e1001284. http://dx.doi.org/10.1371/journal.ppat.1001284.
62. Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA. 2005. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 343:256-266. http://dx.doi.org/10.1016/j.virol.2005.09.059.
63. Puigdomenech I, Casartelli N, Porrot F, Schwartz O. 2013. SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. J. Virol. 87:2846-2856. http://dx.doi.org/10.1128/JVI.02514-12.
64. Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, Laumond G, Decoville T, Holl V, Moog C. 2014. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS 28:667-677. http://dx.doi.org /10.1097/QAD.0000000000000193.
65. Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R. 2014. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7:46-56. http://dx.doi.org/10.1038/mi.2013.23.